Login / Signup

Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers.

Risako OzawaTadaaki NishikawaHiroshi YoshidaKouya ShiraishiTatsunori ShimoiTomoyasu KatoKan Yonemori
Published in: Journal of gynecologic oncology (2024)
methylation cases due to its high sensitivity. Further studies are needed to determine whether EPM2AIP1 IHC can predict pembrolizumab efficacy.
Keyphrases
  • advanced non small cell lung cancer
  • randomized controlled trial
  • systematic review
  • genome wide
  • dna methylation
  • case control
  • endometrial cancer
  • epidermal growth factor receptor